Literature DB >> 33201338

Evaluation of Apelin/APJ system expression in hepatocellular carcinoma as a function of clinical severity.

Manuela Cabiati1, Melania Gaggini1, Paolo De Simone2, Silvia Del Ry3.   

Abstract

Apelin, a peptide of 77 amino acids, and its endogenous ligand, angiotensin-like-receptor 1 (APJ), play a key role in the development of tumors by enhancing angiogenesis, metastasis, cell proliferation, development of cancer stem cells and drug resistance and inhibiting apoptosis of cancer cells. However, little is known about Apelin/APJ system involvement in hepatocellular carcinoma (HCC). The aim of this study was to evaluate Apelin and APJ expression in liver specimens, obtained from subjects with HCV-positive HCC who underwent liver transplantation, according to liver disease severity (liver recipients, LR, n = 14, age 59.4 ± 1.8) and in donors (liver donors, LD, n = 14, age 62.1 ± 17.3). Apelin/APJ axis, apoptotic and inflammatory markers were evaluated by Real-Time PCR analysis. The Apelin/APJ system expression resulted significantly higher in LR in comparison with LD (p < 0.05), in particular in those with more severe liver disease. The apoptotic (Bcl-2, BAX, NOTCH-1, Casp-3) and inflammatory (IL-6, TNF-α) markers were increased as a function of disease severity (p < 0.05). Multiple significant positive correlations were found between Apelin/APJ axis and the other markers. Although further investigations are needed to better understand the role of Apelin/APJ axis in HCC, our result indicated a potential role of this axis in its development and progression as well as in recognizing novel therapeutic targets opening a new avenue for treatment.

Entities:  

Keywords:  Apelin/APJ axis; Apoptosis; Hepatocellular carcinoma; Real-Time PCR

Year:  2020        PMID: 33201338     DOI: 10.1007/s10238-020-00672-x

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  38 in total

1.  MELD and PELD: application of survival models to liver allocation.

Authors:  R H Wiesner; S V McDiarmid; P S Kamath; E B Edwards; M Malinchoc; W K Kremers; R A Krom; W R Kim
Journal:  Liver Transpl       Date:  2001-07       Impact factor: 5.799

Review 2.  Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis.

Authors:  Asmaa-Ibrahim Gomaa; Shahid-A Khan; Mireille-B Toledano; Imam Waked; Simon-D Taylor-Robinson
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

Review 3.  Wnt/beta-catenin pathway in hepatocellular carcinoma pathogenesis and liver physiology.

Authors:  Catherine Cavard; Sabine Colnot; Virginie Audard; Samira Benhamouche; Laetitia Finzi; Cyril Torre; Gisèle Grimber; Cécile Godard; Benoit Terris; Christine Perret
Journal:  Future Oncol       Date:  2008-10       Impact factor: 3.404

Review 4.  Current challenges and future directions for liver transplantation.

Authors:  Pierluigi Toniutto; Alberto Zanetto; Alberto Ferrarese; Patrizia Burra
Journal:  Liver Int       Date:  2016-10-02       Impact factor: 5.828

Review 5.  Targeting receptor tyrosine kinase pathways in hepatocellular carcinoma.

Authors:  Hung Huynh; Richard Wei Jie Ong; Peter Yi Qing Li; Swee Shean Lee; Shu Yang; Lih Wen Chong; Danh Anh Tuan Luu; Chun Tzen Jong; Irene Wei Ling Lam
Journal:  Anticancer Agents Med Chem       Date:  2011-07       Impact factor: 2.505

Review 6.  HCC and angiogenesis: possible targets and future directions.

Authors:  Andrew X Zhu; Dan G Duda; Dushyant V Sahani; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2011-03-08       Impact factor: 66.675

Review 7.  Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.

Authors:  Qian Zhou; Vivian W Y Lui; Winnie Yeo
Journal:  Future Oncol       Date:  2011-10       Impact factor: 3.404

8.  Model for end-stage liver disease (MELD) and allocation of donor livers.

Authors:  Russell Wiesner; Erick Edwards; Richard Freeman; Ann Harper; Ray Kim; Patrick Kamath; Walter Kremers; John Lake; Todd Howard; Robert M Merion; Robert A Wolfe; Ruud Krom
Journal:  Gastroenterology       Date:  2003-01       Impact factor: 22.682

9.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

Review 10.  Hepatocelluar nodules in liver cirrhosis: hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis.

Authors:  Osamu Matsui; Satoshi Kobayashi; Junichiro Sanada; Wataru Kouda; Yasuji Ryu; Kazuto Kozaka; Azusa Kitao; Koichi Nakamura; Toshifumi Gabata
Journal:  Abdom Imaging       Date:  2011-06
View more
  4 in total

Review 1.  Molecular pathways in viral hepatitis-associated liver carcinogenesis: An update.

Authors:  Gulsum Ozlem Elpek
Journal:  World J Clin Cases       Date:  2021-07-06       Impact factor: 1.337

Review 2.  Study Progression of Apelin/APJ Signaling and Apela in Different Types of Cancer.

Authors:  Longfei Liu; Xiaoping Yi; Can Lu; Yong Wang; Qiao Xiao; Liang Zhang; Yingxian Pang; Xiao Guan
Journal:  Front Oncol       Date:  2021-04-12       Impact factor: 6.244

3.  Data mining of key genes expression in hepatocellular carcinoma: novel potential biomarkers of diagnosis prognosis or progression.

Authors:  Manuela Cabiati; Melania Gaggini; Paolo De Simone; Silvia Del Ry
Journal:  Clin Exp Metastasis       Date:  2022-04-16       Impact factor: 4.510

Review 4.  Melanoma Progression under Obesity: Focus on Adipokines.

Authors:  Joanna Olszańska; Katarzyna Pietraszek-Gremplewicz; Dorota Nowak
Journal:  Cancers (Basel)       Date:  2021-05-10       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.